HAE Stock Overview
A healthcare company, provides suite of medical products and solutions in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Haemonetics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$84.92 |
| 52 Week High | US$97.97 |
| 52 Week Low | US$70.25 |
| Beta | 0.32 |
| 11 Month Change | 13.42% |
| 3 Month Change | 12.48% |
| 1 Year Change | 3.59% |
| 33 Year Change | 53.53% |
| 5 Year Change | -30.99% |
| Change since IPO | 1,330.23% |
Recent News & Updates
Recent updates
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
Sep 09
What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E
Aug 14Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?
Jul 18Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Jun 21Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?
Apr 30Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion
Apr 12Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Mar 07Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Mar 06The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business
Feb 15The Price Is Right For Haemonetics Corporation (NYSE:HAE)
Jan 01Haemonetics: Solid Performance Of This Blood Play
Nov 22Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today
Nov 14Is Haemonetics (NYSE:HAE) A Risky Investment?
Oct 24Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment
Oct 13Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains
Aug 09Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors
Aug 09An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued
Jul 25Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Jul 07Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Apr 06Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?
Mar 19Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer
Feb 16Haemonetics: Earnings Rate Of Change Justifies High Multiples
Feb 01We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease
Jan 05Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?
Dec 15Haemonetics Q2 2023 Earnings Preview
Nov 04Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly
Oct 04Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy
Sep 06Haemonetics reaches new 52-week high; shares up 41% YTD
Aug 24Haemonetics reports Q2 earnings beat; raises FY22 guidance
Aug 10A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)
Aug 10Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly
Jul 03Shareholder Returns
| HAE | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -7.5% | -0.4% | -1.0% |
| 1Y | 3.6% | 20.3% | 30.3% |
Return vs Industry: HAE underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: HAE underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| HAE volatility | |
|---|---|
| HAE Average Weekly Movement | 4.9% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HAE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HAE's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 3,657 | Chris Simon | www.haemonetics.com |
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital’s blood bank information system.
Haemonetics Corporation Fundamentals Summary
| HAE fundamental statistics | |
|---|---|
| Market cap | US$4.26b |
| Earnings (TTM) | US$123.81m |
| Revenue (TTM) | US$1.36b |
34.4x
P/E Ratio3.1x
P/S RatioIs HAE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HAE income statement (TTM) | |
|---|---|
| Revenue | US$1.36b |
| Cost of Revenue | US$616.86m |
| Gross Profit | US$744.37m |
| Other Expenses | US$620.56m |
| Earnings | US$123.81m |
Last Reported Earnings
Sep 28, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.47 |
| Gross Margin | 54.68% |
| Net Profit Margin | 9.10% |
| Debt/Equity Ratio | 139.6% |
How did HAE perform over the long term?
See historical performance and comparison